BAFNA PHARMACEUTICALS
|
The Current P/E Ratio of BAFNA PHARMACEUTICALS is 29.14.
| Share Price | ₹118.9 | Mar 23,2026 |
| Market Cap | ₹281.7 Cr | |
| Earnings-TTM | ₹9.7 Cr | TTM-Standalone Results |
| Price/Earnings | 29.14x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of BAFNA PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹281.7 Cr] as on Mar 23,2026
(/) Earnings [ ₹9.7 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 29.14x ]
Thus, for BAFNA PHARMACEUTICALS , the investors are currently willing to pay 29.14 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of BAFNA PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of BAFNA PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of BAFNA PHARMACEUTICALS
PE Ratio Performance Analysis for BAFNA PHARMACEUTICALS
- BAFNA PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 39.60x.
- BAFNA PHARMACEUTICALS 's operated at median p/e ratio of 42.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, BAFNA PHARMACEUTICALS 's p/e ratio peaked in Mar2022 at 57.59x.
- BAFNA PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 17.24x.
How does BAFNA PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| BAFNA PHARMACEUTICALS | 9.67 | 29.14 | 281.7 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 38.30 | 421,407.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 64.38 | 159,596.0 |
| CIPLA LTD | 4,544.70 | 21.73 | 98,767.6 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 62.77 | 142,619.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.98 | 104,544.0 |
| MANKIND PHARMA LTD | 1,796.65 | 44.17 | 79,364.2 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 17.55 | 86,591.5 |
| LUPIN LTD | 4,669.18 | 22.49 | 104,992.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 21.15 | 74,302.0 |
| ABBOTT INDIA LTD | 1,524.13 | 35.51 | 54,123.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs BAFNA PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.55x |
| Max industry PE | 64.38x |
| Median industry PE | 29.14x |
| Average industry PE | 34.20x |
You may also like the below Video Courses